Development of a Liquid Chromatography High Resolution Mass Spectrometry (LC-HRMS) Method for the Quantitation of Viral Envelope Glycoprotein in Ebola Virus-Like Particle Vaccine Preparations
Abstract
Ebola virus like particles; (EBOV VLPs, eVLPs), are produced by expressing the viral transmembrane glycoprotein (GP) and the structural matrix protein VP40 in mammalian cells. When expressed, these proteins self-assemble and bud from host cells displaying morphology similar to infectious virions. Several studies have shown that rodents and non-human primates vaccinated with eVLPs are protected from lethal EBOV challenge. The mucin-like domain of envelope glycoprotein (GP1) serves as the major target for a productive humoral immune response. Therefore GP1 concentration is a critical quality attribute of EBOV vaccines and accurate measurement of the amount of GP1 present in eVLP lots is crucial to understanding variability in vaccine efficacy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 05, 2016
- Accession Number
- AD1021613
Entities
People
- Chris Mahone
- Ernie Brueggemann
- Jonathan E. Nuss
- Karen A Martins
- Lisa H Cazares
- Michael D. Ward
- Paul Demond
- Sina Bavari
- Tara Kenny
- Trevor Glaros
Organizations
- United States Army Medical Research Institute of Infectious Diseases